A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome

Molecular Pharmacology

Volumn 70, Issue 1, 2006, Pages 426-433

  Achanta, Geetha ^a   Modzelewska, Aneta ^b   Feng, Li ^a   Khan, Saeed R ^b   Huang, Peng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3,5 BIS (4 BORONIC ACID BENZYLIDENE) 1 METHYL PIPERIDIN 4 ONE; AM 114; BORONIC ACID DERIVATIVE; CELL PROTEIN; CHALCONE DERIVATIVE; CHYMOTRYPSIN; PROTEASOME; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN INTERACTION;

ANTINEOPLASTIC AGENTS; BORON COMPOUNDS; BORONIC ACIDS; CELL SURVIVAL; CHALCONES; COLONIC NEOPLASMS; FLOW CYTOMETRY; HCT116 CELLS; HUMANS; IMMUNOBLOTTING; MOLECULAR STRUCTURE; MUTATION; PIPERIDINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION-SENSITIZING AGENTS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 33745276531     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.021311     Document Type: Article

References (30)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, and Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622.
2. Balint EE and Vousden KH (2001) Activation and activities of the p53 tumour suppressor protein. Br J Cancer 85:1813-1823.
3. Breitschopf K, Zeiher AM, and Dimmeler S (2000) Ubiquitin-mediated degradation of the proapoptotic active form of bid: a functional consequence on apoptosis induction. J Biol Chem 275:21648-21652.
4. Brooks CL and Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171.
5. Chung AS, Guan YJ, Yuan ZL, Albina JE, and Chin (2005) YE Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II. Mol Cell Biol 25:4716-4726.
6. de Vincenzo R, Scambia G, and Mancuso S (1995) Effect of synthetic and naturally occurring chalcones on ovarian cancer cell growth: structure-activity relationships. Anticancer Drug Des 10:481-490.
7. Dietrich P, Rideout HJ, Wang Q, and Stefanis L (2003) Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. Mol Cell Neurosci 24:430-441.
8. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, and Anderson KC (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076.
9. Hofseth LJ, Hussain SP, and Harris CC (2004) p53: 25 years after its discovery. Trends Pharmacol Sci 25:177-181.
10. Ii T, Satomi Y Katoh D, Shimada J, Baba M, Okuyama T, Nishino H, and Kitamura N (2004) Induction of cell cycle arrest and p21(CIP1/WAF1) expression in human lung cancer cells by isoliquiritigenin. Cancer Lett 207:27-35.
11. Kessova IG and Cederbaum AI (2005) The effect of CYP2E1-dependent oxidant stress on activity of proteasomes in HepG2 cells. J Pharmacol Exp Ther 315:304-312.
12. Kim I, Kim CH, Lee J, Choi JJ, Chen ZA, Lee MG, Chung KC, Hsu CY, and Ahn YS (2004) Pyrrolidine dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp Cell Res 298:229-238.
13. Kumar SK, Hager E, Pettit C, Gurulingappa H, Davidson NE, and Khan SR (2003) Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J Med Chem 46:2813-2815.
14. Li B and Dou QP (2000) Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 97:3850-3855.
15. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, and Perez-Soler R (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154.
16. Lyakhovich A and Shekhar MP (2003) Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. Mol Cell Biol 23:2463-2475.
17. MacLaren AP, Chapman RS, Wyllie AH, and Watson CJ (2001) p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ 8:210-218.
18. Makita H, Tanaka T, Fujitsuka H, Tatematsu N, Satoh K, Hara A, and Mori H (1996) Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin. Cancer Res 56:4904-4909.
19. Marteijn JA, van Emst L, Erpelinck-Verschueren CA, Nikoloski G, Menke A, de Witte T, Lowenberg B, Jansen JH, and van der Reijden BA (2005). The E3 ubiquitin-protein ligase Triad1 inhibits clonogenic growth of primary myeloid progenitor cells. Blood 106:4114-4123.
20. Sabzevari O, Galati G, Moridani MY, Siraki A, and O'Brien PJ (2004) Molecular cytotoxic mechanisms of anticancer hydroxychalcones. Chem Biol Interact 148:57-67.
21. Satomi Y (1993) Inhibitory effects of 3′-methyl-3-hydroxy-chalcone on proliferation of human malignant tumor cells and on skin carcinogenesis. Int J Cancer 55:506-514.
22. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, and Callery MP (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82:110-112.
23. Shibata S (1994) Anti-tumorigenic chalcones. Stem Cells 12:44-52.
24. Stoll R, Renner C, Hansen S, Palme S, Klein C, Belling A, Zeslawski W, Kamionka M, Rehm T, Mühlhahn P, et al. (2001) Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40:336-344.
25. Wattenberg LW, Coccia JB, and Galbraith AR (1994) Inhibition of carcinogen-induced pulmonary and mammary carcinogenesis by chalcone administered subsequent to carcinogen exposure. Cancer Lett 83:165-169.
26. Williams SA and McConkey DJ (2003) The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res 63:7338-7344.
27. Yamamoto S, Aizu E, Jiang H, Nakadate T, Kiyoto I, Wang JC, and Kato R (1991) The potent anti-tumor-promoting agent isoliquiritigenin. Carcinogenesis 12:317-323.
28. Yang EB, Guo YJ, Zang K Chen YZ, and Mack P (2001) Inhibition of epidermal growth factor receptor tyrosine kinase by chalcone derivatives. Biochim Biophys Acta 1150:144-152.
29. Yee KS and Vousden KH (2005) Complicating the complexity of p53.Carcinogenesis 26:1317-1322.
30. Zhang Q, Tian L, Mansouri A, Korapati AL, Johnson TJ, and Claret FX (2005) Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Lett 579:3932-3940.